Latest News and Press Releases

    Tetra to partner with a Contract Sales Organization (CSO) for both TERPACAN™ and AWAYE™              Tetra expanding sales partnership agreements to the Middle East      OTTAWA, Jan. 20, 2020 ...

FDA Feedback continues to support the development of QIXLEEF for second- or third-line therapy for adult patients with uncontrolled pain FDA advice consistent with previous feedback paving the way...

Submitted data to U.S. Food and Drug Administration for surrogate endpoint to be used for an Accelerated Approval              Two OTC DIN applications pass Health Canada screening phase OTTAWA,...

OTTAWA, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today announced...

Orphan Drug Designation qualifies Tetra for certain incentives and benefits, including a 50% tax credit upon approval               Tetra to pursue 505(b)(2) NDA pathway and expedited review for its...

Tetra to launch Phase 2 trial for treatment of hepatocellular carcinoma in Q1 2020              Tetra leverages Caumz™-kit technology to provide a new drug for cancer treatment OTTAWA, Dec. 04,...

Alternavida to launch and fund 2 clinical sites in Mexico as part of the clinical research collaboration in the commercialization agreement           Collaboration potentially allows Tetra to...

OTTAWA, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Tetra Natural Health (“TNH”) a wholly owned subsidiary of Tetra Bio-Pharma Inc., (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF) today announced that...

Company to resume clinical trial in advanced cancer patients with uncontrolled painTetra engages leading clinical collaborator to run Plenitude trial in the U.S. OTTAWA, Nov. 25, 2019 (GLOBE...

OTTAWA, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., (TSX-V: TBP) (OTCQB: TBPMF), a leader in drug discovery and development for cannabinoid-based therapeutics, today announced its...